U.S. markets close in 5 hours 26 minutes
  • S&P 500

    4,576.23
    +1.44 (+0.03%)
     
  • Dow 30

    35,701.48
    -55.40 (-0.15%)
     
  • Nasdaq

    15,295.76
    +60.04 (+0.39%)
     
  • Russell 2000

    2,286.82
    -9.26 (-0.40%)
     
  • Crude Oil

    83.93
    -0.72 (-0.85%)
     
  • Gold

    1,787.40
    -6.00 (-0.33%)
     
  • Silver

    24.06
    -0.03 (-0.14%)
     
  • EUR/USD

    1.1617
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.5920
    -0.0270 (-1.67%)
     
  • GBP/USD

    1.3734
    -0.0029 (-0.21%)
     
  • USD/JPY

    113.7270
    -0.4020 (-0.35%)
     
  • BTC-USD

    58,961.34
    -3,147.78 (-5.07%)
     
  • CMC Crypto 200

    1,413.75
    -60.58 (-4.11%)
     
  • FTSE 100

    7,261.10
    -16.52 (-0.23%)
     
  • Nikkei 225

    29,098.24
    -7.77 (-0.03%)
     

Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day.

Event:

Oppenheimer Rare & Orphan Disease Summit

Date:

May 21, 2021

Time:

Live Presentation 10:45 AM – 11:25 AM (ET)

The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay will be available for 90 days. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Summit or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.